Eli Lilly and Junshi Biosciences are collaborating to develop therapeutic antibodies for preventing and treating COVID-19.
The Chinese drugmaker launched one of the first research and development efforts for COVID-19 therapies at the beginning of the outbreak. It has already engineered multiple neutralizing antibodies aimed at neutralizing the virus and the lead candidate is expected to enter clinical testing in the coming weeks.
Lilly will receive an exclusive license to conduct clinical development, manufacturing and distribution of products outside of Greater China. Junshi Biosciences will maintain all rights in Greater China.